Healthcare of Ontario Pension Plan Trust Fund Has $397,000 Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

Healthcare of Ontario Pension Plan Trust Fund lessened its position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 35.0% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 33,500 shares of the specialty pharmaceutical company’s stock after selling 18,000 shares during the period. Healthcare of Ontario Pension Plan Trust Fund owned 0.08% of KalVista Pharmaceuticals worth $397,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Tower Research Capital LLC TRC increased its stake in shares of KalVista Pharmaceuticals by 28.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,482 shares of the specialty pharmaceutical company’s stock valued at $43,000 after buying an additional 768 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in shares of KalVista Pharmaceuticals during the fourth quarter worth about $49,000. AJOVista LLC bought a new position in shares of KalVista Pharmaceuticals during the fourth quarter worth about $60,000. SG Americas Securities LLC grew its stake in KalVista Pharmaceuticals by 5.1% during the fourth quarter. SG Americas Securities LLC now owns 137,817 shares of the specialty pharmaceutical company’s stock worth $1,688,000 after purchasing an additional 6,670 shares during the period. Finally, BNP Paribas Financial Markets grew its stake in KalVista Pharmaceuticals by 94.5% during the first quarter. BNP Paribas Financial Markets now owns 18,013 shares of the specialty pharmaceutical company’s stock worth $214,000 after purchasing an additional 8,750 shares during the period.

Wall Street Analyst Weigh In

Several research firms recently commented on KALV. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research note on Monday, July 15th. Needham & Company LLC decreased their target price on KalVista Pharmaceuticals from $35.00 to $32.00 and set a “buy” rating for the company in a research note on Friday, July 12th.

Insider Buying and Selling at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 7,465 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $11.53, for a total transaction of $86,071.45. Following the transaction, the chief executive officer now owns 224,547 shares of the company’s stock, valued at $2,589,026.91. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CEO Benjamin L. Palleiko sold 7,465 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Friday, June 7th. The stock was sold at an average price of $11.53, for a total transaction of $86,071.45. Following the transaction, the chief executive officer now owns 224,547 shares of the company’s stock, valued at $2,589,026.91. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 21,959 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.76, for a total value of $258,237.84. Following the transaction, the chief executive officer now directly owns 216,387 shares in the company, valued at approximately $2,544,711.12. The disclosure for this sale can be found here. Over the last quarter, insiders sold 37,512 shares of company stock valued at $439,424. Company insiders own 12.30% of the company’s stock.

KalVista Pharmaceuticals Price Performance

Shares of KalVista Pharmaceuticals stock opened at $14.39 on Friday. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.21 and a 52 week high of $16.88. The stock has a 50 day moving average price of $12.34 and a two-hundred day moving average price of $12.62.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its quarterly earnings data on Thursday, July 11th. The specialty pharmaceutical company reported ($1.02) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.29). As a group, sell-side analysts predict that KalVista Pharmaceuticals, Inc. will post -3.38 earnings per share for the current year.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.